Mycovia Pharmaceuticals Expands Commercialization Team with Strategic New Hires

Laura Randa to lead market access, HEOR and public policy, and Mare Lynn Fitch to lead marketing strategy as company advances oteseconazole (VT-1161), the potential first FDA-approved treatment for recurrent vulvovaginal candidiasis

Durham, N.C. – January 21, 2020 – Mycovia Pharmaceuticals, Inc. (“Mycovia”) today announced the appointments of Laura Randa as Vice President, Market Access, Health Economics and Outcomes Research, and Public Policy, and Mare Lynn Fitch as Senior Director, Marketing. In these roles, Ms. Randa and Ms. Fitch will advance strategic commercialization efforts for Mycovia’s future product launches and contribute to driving long-term growth of the company. Mycovia is developing oteseconazole (VT-1161), an oral antifungal product candidate, for the treatment of Recurrent Vulvovaginal Candidiasis (RVVC), a debilitating, chronic infectious condition that affects nearly 138 million women worldwide each year and for which there is currently no FDA-approved treatment in the U.S.